Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial

(2014) F.P. Vanhoutte et al.   ANNALS OF THE RHEUMATIC DISEASES

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

The JAK-STAT Pathway at Twenty

(2012) George R. Stark et al.   IMMUNITY

Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2

(2012) Mark Zak et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors

(2012) Janusz J. Kulagowski et al.   JOURNAL OF MEDICINAL CHEMISTRY

The IL-23/IL-17 pathway in inflammatory bowel disease

(2012) Alessandra Geremia et al.   Expert Review of Gastroenterology & Hepatology

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

(2011) K. Shide et al.   BLOOD

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective

(2011) A. Tefferi et al.   BLOOD REVIEWS

New JAK2 inhibitors for myeloproliferative neoplasms

(2011) Alfonso Quintás-Cardama et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo

(2011) M. Ishizaki et al.   JOURNAL OF IMMUNOLOGY

Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors

(2011) Laurie B. Schenkel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 Holocomplex

(2011) Patrick J. Lupardus et al.   STRUCTURE

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

(2011) Kristine L Stump et al.   ARTHRITIS RESEARCH & THERAPY

Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3

(2010) Jeremiah P. Malerich et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Kinase inhibitors: a new approach to rheumatoid arthritis treatment

(2010) Stanley Cohen et al.   CURRENT OPINION IN RHEUMATOLOGY

Recent developments on JAK2 inhibitors: a patent review

(2010) Róbert Kiss et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Recent patents in the discovery of small molecule inhibitors of JAK3

(2010) Lawrence J Wilson   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family

(2010) Gebhard Thoma et al.   JOURNAL OF MEDICINAL CHEMISTRY

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2

(2008) F. Grebien et al.   BLOOD